Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting

Translational Oncology

Volumn 8, Issue 6, 2015, Pages 474-479

  Lu, Chien Yu ^a,b   Huang, Ching Wen ^a,b,c   Wu, I Chen ^a,b   Tsai, Hsiang Lin ^a,b,d   Ma, Cheng Jen ^a,b   Yeh, Yung Sung ^a,c   Chang, Se Fen ^a   Huang, Meng Lin ^e   Wang, Jaw Yuan ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d FOOYIN UNIVERSITY   (Taiwan)

^e ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DRUG DOSE ESCALATION; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL;

EID: 84949784176     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.11.002     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Saunders M and Iveson T (2006). Management of advanced colorectal cancer: state of the art. Br J Cancer 95, 131-138.
3. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7, 2182-2194.
4. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101, 847-854.
5. Monaghan G, Ryan M, Seddon R, Hume R, and Burchell B (1996). Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581.
6. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002). UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2, 43-47.
7. Marcuello E, Paez D, Pare L, Salazar J, Sebio A, del Rio E, and Baiget M (2011). A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 105, 53-57.
8. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, and Lo Re G, et al (2010). Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 28, 866-871.
9. Palomaki GE, Bradley LA, Douglas MP, Kolor K, and Dotson WD (2009). Can UGT1A1genotyping reduce morbidity and mortality in patientswithmetastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11, 21-34.
10. Hebbar M, Ychou M, and Ducreux M (2009). Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 135, 749-752.
11. Tsai H-L, Chen C-F, Lu C-Y, Fang W-Y, Wu D-C, Wu I-C, Sheen M-C, Lin S-R, and Wang J-Y (2009). Significant Correlation between Polymorphisms of UGT1A1 Gene and Low Irinotecan Toxicity in Colorectal Cancer Patients with FOLFIRI. Open Colorectal Cancer J 2, 21-26.
12. VanCutsem E,Kohne CH,Hitre E,Zaluski J,Chang ChienCR, Makhson A,D'Haens G, Pinter T, Lim R, and Bodoky G, et al (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408-1417.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, and Holmgren E, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
14. Peeters M and Price T (2012). Biologic therapies in the metastatic colorectal cancer treatment continuum-applying current evidence to clinical practice. Cancer Treat Rev 38, 397-406.
15. Yeh YS, Huang ML, Chang SF, Chen CF, Hu HM, and Wang JY (2014). FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. Med Princ Pract 23, 478-481.
16. LuCY,HuangCW,HuHM, Tsai HL, HuangCM, Yu FJ, HuangMY, Chang SF, Huang ML, and Wang JY (2014). Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. Transl Res 164, 169-176.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, andMooney M, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45, 228-247.
18. Macedo LT, da Costa Lima AB, and Sasse AD (2012). Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMCCancer 12, 89-96.
19. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, and Thibodeau SN, et al (2010). Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28, 3227-3233.
20. Cartwright TH (2012). Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 11, 155-166.
21. Gill S, Blackstock AW, and Goldberg RM (2007). Colorectal cancer. Mayo Clin Proc 82, 114-129.
22. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, and Cassidy J (2009). Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101, 1033-1038.
23. Figueras J, Lopez-Ben S, Alsina M, Soriano J, Hernandez-Yague X, Albiol M, Guardeno R, Codina-Barreras A, and Queralt B (2013). Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. Clin Transl Oncol 15, 460-466.
24. Bruera G, Cannita K,Giuliante F, Lanfiuti Baldi P, Vicentini R,Marchetti P, Nuzzo G, Antonucci A, Ficorella C, andRicevuto E (2012). Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer 11, 119-126.
25. Hu ZY, Yu Q, and Zhao YS (2010). Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 46, 1856-1865.
26. Hu ZY, Yu Q, Pei Q, and Guo C (2010). Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16, 3832-3842.
27. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, and McLeod HL (2007). UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99, 1290-1295.
28. O'Dwyer PJ and Catalano RB (2006). Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24, 4534-4538.
29. BergAO, Armstrong K, Botkin J, CalongeN,Haddow J,Hayes M, Kaye C, Phillips KA, PiperM, and Richards CS, et al (2009). Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 11, 15-20.
30. Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, and Rennert G (2011). Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117, 3156-3162.
31. Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, and Horie K, et al (2009). Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multiinstitutional study. Oncology 76, 315-321.
32. Hazama S,MishimaH, Tsunedomi R,Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, and Takemoto H, et al (2013).UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 104, 1662-1669.